The CAQK peptide, consisting of four amino acids, has demonstrated potent protective effects on the brain in animal models of traumatic brain injury.It is administered by standard intravenous infusion shortly after injury and targets damaged brain tissue.1[2] It binds to the protein tenascin-C in the extracellular matrix, which increases after trauma.[3] CAQK has been shown to be a potent protective agent in the brain.1][2] In mice and pigs, it reduces inflammation, cell death, and lesion size compared to controls.[1][2][7] In mice, it improves functional recovery, behavior, and memory with no apparent toxicity.[1][2] Researchers are preparing for early clinical trials in humans.[1][3] In mice, it improves functional recovery, behavior, and memory with no apparent toxicity.